Individuals on SGLT2 inhibitors (with and without diabetes) had a significant reduction in risk of all-cause death compared to non-SGLT2i users, according to population-based cohort research in Taiwan that included 399,810 patients newly diagnosed with T2M. Here, SLC5A2 is linked to diabetes mellitus.